Self‐reported pain (dysmenorrhoea) (dichotomous data) ‐ reduction of pain to zero at 6 months' · women with endometriosis
It is very uncertain whether combined oral contraceptive pill changes self‐reported pain (dysmenorrhoea) (dichotomous data): reduction of… compared with other medical treatment (very low certainty).
2 findings from 1 review
Oral pain · Patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region
Polaprezinc led to lower oral pain (severe, > 2 on 0-3 scale) compared with azulene oral rinse; GRADE not reported.
1 finding from 1 review
Live birth or ongoing pregnancy · women undergoing assisted reproduction
Combined oral contraceptive pill probably leads to lower live birth or ongoing pregnancy (COCP + Ant vs Ant) compared with no pretreatment (moderate certainty).
2 findings from 1 review
Pregnancy loss · women undergoing assisted reproduction
Combined oral contraceptive pill showed no clear difference in pregnancy loss (COCP + Ant vs Ant) compared with no pretreatment (moderate certainty).
2 findings from 1 review
Multiple pregnancy rate · women undergoing assisted reproduction
Combined oral contraceptive pill showed no clear difference in multiple pregnancy rate (COCP + Ant vs Ant) compared with no pretreatment (low certainty).
2 findings from 1 review
OHSS · women undergoing assisted reproduction
Combined oral contraceptive pill showed no clear difference in OHSS rate (COCP + Ant vs Ant) compared with no pretreatment (low certainty).
2 findings from 1 review
Disability of oral intake · Patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region
Polaprezinc showed no clear difference in disability of oral intake compared with azulene oral rinse; GRADE not reported.
1 finding from 1 review
Change in weight (kg) · children with chronic disease
1 finding from 1 review
Change in weight z score · children with chronic disease
1 finding from 1 review
Change in height · children with chronic disease
1 finding from 1 review
Change in BMI · children with chronic disease
1 finding from 1 review
Change in total calories (Kcal/day): at 12 months · children with chronic disease
1 finding from 1 review
Change in total protein intake (g/day) at 3 months · children with chronic disease
1 finding from 1 review
FEV1 · children with chronic disease
1 finding from 1 review
Death (all causes) · people with CKD
Patient‐centred outcomes for oral showed no clear difference in death (all causes) compared with IV iron (low certainty).
1 finding from 1 review
Cardiovascular mortality · people with CKD
It is very uncertain whether patient‐centred outcomes for oral changes cardiovascular death compared with IV iron (very low certainty).
1 finding from 1 review
Type of adverse event: allergic reactions/hypotension · people with CKD
Patient‐centred outcomes for oral may leads to higher type of adverse event: allergic reactions/hypotension compared with IV iron (low certainty).
1 finding from 1 review
Gastrointestinal effects · people with CKD
Patient‐centred outcomes for oral may leads to lower type of adverse event: all gastrointestinal adverse effects compared with IV iron (low certainty).
1 finding from 1 review
Type of adverse event: infection · people with CKD
Patient‐centred outcomes for oral showed no clear difference in type of adverse event: infection compared with IV iron (low certainty).
1 finding from 1 review
Numbers of non‐dialysis patients needing to commence dialysis · people with CKD
Patient‐centred outcomes for oral showed no clear difference in numbers of non‐dialysis patients needing to commence dialysis compared with IV iron (low certainty).
1 finding from 1 review